Responding to the study published today in the Science Translational Medicine, showing that the drug Fevipiprant reduces the amount of muscle in the lining of the airway, which can cause asthma symptoms and over time contribute to ‘remodelling’ of the airway, Dr Samantha Walker, Director of Research and Policy at Asthma UK, said:
“The development of a tablet to treat asthma symptoms and potentially prevent lung damage is exciting progress which could, in time, lead to the development of new treatments.
“Around 200,000 people have severe asthma, a type of asthma which responds poorly to the usual inhaled asthma treatments and leads patients to rely on oral steroid tablets which can have toxic long-term side effects. Severe asthma is a debilitating condition, causing life-threatening asthma attacks and countless hospital admissions.
“While the tablet is still some way off being available, and we don’t yet know who would be eligible for it, these results are very encouraging. More research is needed in larger numbers of people to establish how effective it is and work out who would benefit.”
For further information, please contact:
Thomas Dearnley-Davison, Senior Social Media & Media Officer, Asthma UK
Landline: 0207 786 4981
OOO: 07951 721 393
About Asthma UK
- In the UK, 5.4 million people are currently receiving treatment for asthma: 1.1 million children (1 in 11) and 4.3 million adults (1 in 12).
- Every day, the lives of three families are devastated by the death of a loved one to an asthma attack, and tragically two thirds of these deaths are preventable.
- Asthma UK’s mission is to stop asthma attacks and cure asthma. We do this by funding world leading research, campaigning for improved care and supporting people to reduce their risk of a potentially life-threatening asthma attack.
- The Asthma UK Helpline is open weekdays from 9am to 5pm on 0300 222 5800.
- For more information about asthma please visit www.asthma.org.uk